Online Adaptive Radiation Therapy for Rectal Cancer
Primary Purpose
Rectal Cancer
Status
Not yet recruiting
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Online adaptive radiation therapy
Sponsored by
About this trial
This is an interventional treatment trial for Rectal Cancer focused on measuring rectal cancer, adaptive radiation therapy
Eligibility Criteria
Inclusion Criteria: ≥18 years old; Diagnose with rectal cancer; T3-T4 or N+, and no distant metastasis Neoadjuvant chemoradiotherapy intended; Surgery is expected after neoadjuvant therapy; ECOG score 0-2, expected to lie in the treatment bed for at least half an hour; Exclusion Criteria: With contraindications to rectal MRI; Received surgery, radiotherapy or chemotherapy for rectal cancer; History of pelvic radiotherapy.
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Online adaptive radiation therapy
Arm Description
Patients receive adaptive radiotherapy therapy and concurrent chemotherapy.
Outcomes
Primary Outcome Measures
Acute toxicities(CTCA
evaluated with Common Terminology Criteria for Adverse Events (CTCAE) 5.0
Response rate after surgery
Clinical and pathological complete response and partial response rate after chemoradiotherapy
Secondary Outcome Measures
Chronic toxicity
evaluated with Radiation Therapy Oncology Group (RTOG)/EORTC late radiation morbidity scoring scheme
Dose coverage of target volume (assessed by planing target volume V100%)
Planing target volume V100%, defined as the planing target volume receiving at least 100% of the prescribed dose (V100%), is used to evaluate the dose coverage of target volume.
Margins for clinical target volume(CTV) and gross tumor volume (GTV)
Margins needed in online ART for CTV to planning clinical target volume (PCTV) and GTV to planning gross tumor volume (PGTV) to cover inter/intra-fraction motion
Full Information
NCT ID
NCT05911789
First Posted
May 25, 2023
Last Updated
July 30, 2023
Sponsor
Peking Union Medical College Hospital
1. Study Identification
Unique Protocol Identification Number
NCT05911789
Brief Title
Online Adaptive Radiation Therapy for Rectal Cancer
Official Title
A Prospective Study to Evaluate Online Adaptive Radiotherapy in Rectal Cancer
Study Type
Interventional
2. Study Status
Record Verification Date
May 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
August 5, 2023 (Anticipated)
Primary Completion Date
June 1, 2024 (Anticipated)
Study Completion Date
June 1, 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Peking Union Medical College Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
In the present study, the investigators will evaluate the efficacy, toxicities, and of online adaptive radiation therapy (ART) for patients with rectal cancer treated with neoadjuvant chemoradiotherapy.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rectal Cancer
Keywords
rectal cancer, adaptive radiation therapy
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
15 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Online adaptive radiation therapy
Arm Type
Experimental
Arm Description
Patients receive adaptive radiotherapy therapy and concurrent chemotherapy.
Intervention Type
Radiation
Intervention Name(s)
Online adaptive radiation therapy
Other Intervention Name(s)
ART
Intervention Description
A dose of 45Gy will be delivered to planning target volume (PTV)
Primary Outcome Measure Information:
Title
Acute toxicities(CTCA
Description
evaluated with Common Terminology Criteria for Adverse Events (CTCAE) 5.0
Time Frame
3 months for the start of treatment
Title
Response rate after surgery
Description
Clinical and pathological complete response and partial response rate after chemoradiotherapy
Time Frame
3 monsh after treatment
Secondary Outcome Measure Information:
Title
Chronic toxicity
Description
evaluated with Radiation Therapy Oncology Group (RTOG)/EORTC late radiation morbidity scoring scheme
Time Frame
2 years after treatment
Title
Dose coverage of target volume (assessed by planing target volume V100%)
Description
Planing target volume V100%, defined as the planing target volume receiving at least 100% of the prescribed dose (V100%), is used to evaluate the dose coverage of target volume.
Time Frame
Through study completion, an average of five month
Title
Margins for clinical target volume(CTV) and gross tumor volume (GTV)
Description
Margins needed in online ART for CTV to planning clinical target volume (PCTV) and GTV to planning gross tumor volume (PGTV) to cover inter/intra-fraction motion
Time Frame
Through study completion, an average of five month
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
≥18 years old;
Diagnose with rectal cancer;
T3-T4 or N+, and no distant metastasis
Neoadjuvant chemoradiotherapy intended;
Surgery is expected after neoadjuvant therapy;
ECOG score 0-2, expected to lie in the treatment bed for at least half an hour;
Exclusion Criteria:
With contraindications to rectal MRI;
Received surgery, radiotherapy or chemotherapy for rectal cancer;
History of pelvic radiotherapy.
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Online Adaptive Radiation Therapy for Rectal Cancer
We'll reach out to this number within 24 hrs